PHIO vs. QNCX, IPSC, KRON, VTVT, ARTV, RNXT, CELU, PEPG, AVTX, and MRSN
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Quince Therapeutics (QNCX), Century Therapeutics (IPSC), Kronos Bio (KRON), vTv Therapeutics (VTVT), Artiva Biotherapeutics (ARTV), RenovoRx (RNXT), Celularity (CELU), PepGen (PEPG), Avalo Therapeutics (AVTX), and Mersana Therapeutics (MRSN). These companies are all part of the "pharmaceutical products" industry.
Phio Pharmaceuticals vs. Its Competitors
Phio Pharmaceuticals (NASDAQ:PHIO) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations.
Phio Pharmaceuticals received 29 more outperform votes than Quince Therapeutics when rated by MarketBeat users. However, 90.91% of users gave Quince Therapeutics an outperform vote while only 65.00% of users gave Phio Pharmaceuticals an outperform vote.
Quince Therapeutics' return on equity of -53.27% beat Phio Pharmaceuticals' return on equity.
Phio Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 466.80%. Quince Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 566.67%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Phio Pharmaceuticals.
In the previous week, Phio Pharmaceuticals had 12 more articles in the media than Quince Therapeutics. MarketBeat recorded 14 mentions for Phio Pharmaceuticals and 2 mentions for Quince Therapeutics. Phio Pharmaceuticals' average media sentiment score of 0.92 beat Quince Therapeutics' score of 0.63 indicating that Phio Pharmaceuticals is being referred to more favorably in the media.
Quince Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 0.6% of Phio Pharmaceuticals shares are held by company insiders. Comparatively, 20.3% of Quince Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Phio Pharmaceuticals has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500.
Summary
Quince Therapeutics beats Phio Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:PHIO) was last updated on 6/13/2025 by MarketBeat.com Staff
